Advertisement
Videos
Advertisement

Novartis and Glaxo Deal Reshapes Pharma Industry

Tue, 04/22/2014 - 8:58am

Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. The WSJ explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading